NEW YORK (GenomeWeb) – Susan G. Komen announced today that it has committed $375,000 in funding to support the Metastatic Breast Cancer (MBC) Project, a collaborative effort led by the Broad Institute and the Dana-Farber Cancer Institute to gather genomic and other data from young breast cancer patients and speed the development of new therapeutics.
Since its launch in October 2015, the project has enrolled more than 2,500 metastatic breast cancer patients throughout the US and Canada.
"This study will not only help improve our understanding of the disparities that exist for younger breast cancer patients, but also inform the development of new treatment strategies for metastatic breast cancer in this population," Komen President and CEO Judy Salerno said in a statement.
Dana-Farber's Nikhil Wagle, who is leading the project, added that the new funding "will help us study the young women and men who have joined the Metastatic Breast Cancer Project, a group of patients who often present with more advanced and aggressive tumors."